Welch & Forbes’s Anika Therapeutics ANIK Stock Holding History

Welch & Forbes’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,161	Closed	-$216K	–	330
2019 Q4	$216K	Buy	+4,161	New	+$242K	﹤0.01%	343

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Welch & Forbes's ANIK Position: Q1 2020 in Review

Welch & Forbes sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 4,161 shares — an estimated $216K sold.

Welch & Forbes first reported a position in ANIK in Q4 2019 and held it in 1 quarter. The position peaked at $216K in Q4 2019. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

Welch & Forbes reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
Welch & Forbes sold 4,161 Anika Therapeutics shares in Q1 2020, an estimated $216K.
Welch & Forbes first reported a position in Anika Therapeutics in Q4 2019 and held it in 1 quarter.
Welch & Forbes's Anika Therapeutics position peaked at $216K in Q4 2019.
163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Welch & Forbes's 13F filing for Q1 2020, filed 17 Apr 2020.